SUNRISE-1
27 evidence topics · 13 sources
Objective
Registry objective: oral VK2735 in adults without type 2 diabetes
Company-stated objective of the SUNRISE program
Location and study date
Company-reported initiation and enrollment status
Study sites shared with the VANQUISH program
Planned start date before initiation
Study design
Randomized, double-blind, placebo-controlled, parallel-arm design
Treatment period, screening, and follow-up
Program structure modeled on the VANQUISH program
FDA end-of-phase 2 meeting for the oral tablet
Eligibility criteria
Inclusion criteria
Company description of the enrolled population
Treatment
Registry arms: doses described as dose levels
“VK2735 Dose level 1 orally once daily” (opens the source at this quote in a new tab)
“VK2735 Dose level 2 orally once daily” (opens the source at this quote in a new tab)
“VK2735 Dose level 3 orally once daily” (opens the source at this quote in a new tab)
“Placebo comparator orally once daily” (opens the source at this quote in a new tab)
Company-stated doses: 27.5 mg, 35 mg, and 55 mg once daily
Dose titration schedule
Rationale for the selected doses: tablet burden and cost of goods
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary endpoint: percent change in body weight at week 68
Secondary and exploratory endpoints
FDA draft guidance: primary efficacy endpoint for weight-reduction drugs
FDA draft guidance: weight reduction indication spans at least one year
Statistical analysis description
Number of participants (Planned and analyzed)
Basis for the reduced sample size: reuse of subcutaneous safety data
Description of analysis sets
Superiority hypothesis for the primary endpoint
Analysis populations
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
SUNRISE-1 had reported no results as of November 2026, and every leaf on disposition, baseline characteristics, efficacy, quality of life, and safety is empty. The design is known only from the ClinicalTrials.gov record, company press releases, an investor presentation, and transcripts of investor calls; no protocol, statistical analysis plan, or peer-reviewed design paper is available.
The registry and the company documents differ on status and on doses. The company announced the program's initiation on October 14, 2026, and its later documents describe the trials as “Underway”, while the registry record still lists the study as “Not yet recruiting” with an estimated start in November 2026. The registry describes the three active arms only as dose levels 1 to 3; the doses of 27.5 mg, 35 mg, and 55 mg are stated in company releases.
The registry record lists one primary outcome and no secondary outcomes, so the responder endpoints and exploratory endpoints (function, metabolic health, mental health, productivity) rest on company documents. The planned enrollment of 560 participants is about 75% smaller than the subcutaneous phase 3 program, a reduction the company attributes to reusing safety data from the subcutaneous trials, which the FDA accepted while noting “risks going from phase II to phase III”. The company states that the doses were chosen in part to lower “the tablet burden” and for gross margin, and gives no exposure-response analysis for them. The FDA's details from the end-of-phase 2 meeting are not public, and the company declined to describe them.